As of April 19, 2025, Cue Biopharma (CUE) has a market cap of $57.417 million USD. According to our data, Cue Biopharma is ranked No.7974 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 19, 2025 | $57.42 M |
-16.85%
|
Dec 31, 2024 | $69.05 M |
-58.71%
|
Dec 29, 2023 | $0.17 B |
-7.37%
|
Dec 30, 2022 | $0.18 B |
-74.80%
|
Dec 31, 2021 | $0.72 B |
-9.59%
|
Dec 31, 2020 | $0.79 B |
-21.20%
|
Dec 31, 2019 | $1.01 B |
237.77%
|
Dec 31, 2018 | $0.30 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Eli Lilly
LLY
|
$754.27 B |
0.008 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$379.48 B |
-0.003 M
|
![]() USA
|
![]() AbbVie
ABBV
|
$306.02 B |
0.008 M
|
![]() USA
|
![]() Novo Nordisk
NVO
|
$285.37 B |
89.978 B
|
![]() Denmark
|
![]() Novo Nordisk A/S
NOVO-B.CO
|
$285.54 B |
69.140 B
|
![]() Denmark
|
![]() Roche
ROG.SW
|
$251.12 B |
35.293 B
|
![]() Switzerland
|
![]() Novartis
NVS
|
$219.89 B |
0.932 B
|
![]() Switzerland
|
![]() AstraZeneca
AZN
|
$210.29 B |
0.735 B
|
![]() UK
|
![]() Merck
MRK
|
$196.28 B |
0.008 M
|
![]() USA
|
![]() Thermo Fisher Scientific
TMO
|
$161.38 B |
-0.001 M
|
![]() USA
|
![]() Amgen
AMGN
|
$149.09 B |
0.124 B
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$130.32 B |
-0.001 M
|
![]() USA
|
![]() Vertex Pharmaceuticals
VRTX
|
$125.74 B |
-0.003 M
|
![]() USA
|
![]() Pfizer
PFE
|
$125.57 B |
0.001 M
|
![]() USA
|
![]() Sanofi
SNY
|
$124.64 B |
0.327 B
|
![]() France
|
![]() Bristol-Myers Squibb
BMY
|
$100.17 B |
-0.004 M
|
![]() USA
|
![]() Chugai Pharmaceutical
4519.T
|
$96.41 B |
0.002 M
|
![]() Japan
|
![]() CVS Health
CVS
|
$84.95 B |
-0.002 M
|
![]() USA
|
![]() CSL
CSL.AX
|
$73.92 B |
0.002 M
|
![]() Australia
|
![]() GlaxoSmithKline
GSK
|
$72.79 B |
-0.000 M
|
![]() UK
|
Market Cap | = | CUE Stock Price | * | CUE Shares Outstanding |
= | $0.76 | * | 75.35 M | |
= | $57.42 M |